Carolien Zeetsen

112 GHB–induced comas are very common in GUD patients, with 84% of users having experienced GHB–induced comas at least once, and often even on a daily basis (Beurmanjer et al., 2019). Therefore, cognitive impairment might result from excessive GHB use and can potentially be an important factor in the high relapse rates observed in GUD patients. To our knowledge no studies on the relationship between cognitive impairment and relapse in patients with GUD have been published to date. This prospective cohort study aimed to investigate in patients with GUD: 1) the association between cognitive impairment, the number of GHB–induced comas and severity of GHB use; and 2) the association between cognitive impairment and relapse in GHB use after detoxification.